Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2138 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 3 of 22 pages < 1 2 3 4 5 > Last ›
HSL6884
Shalansky S.
Conflicting opinions on conflict of interest
Canadian Journal of Hospital Pharmacy 1999; 52:67-68
HSL6885
Smith D
The ties that bind? Weighing the risks and benefits of pharmaceutical industry sponsorship
Amsterdam: Health Action Interaction 1999
www.haiweb.org
HSL6914
Haynes RB.
Drug dependence in a journal club: Editor's response
ACP Journal Club 1999; 131:(3):A13
http://www.acpjc.org/Content/131/3/ISSUE/ACPJC-1999-131-3-A13.htm
HSL7844
Jones M, Greenfield S, Bradley C.
Survey of the advertising of nine new drugs in the general practice literature
Journal of Clinical Pharmacy and Therapeutics 1999; 24:(6):451-460
www.blackwell-synergy.com/rd.asp?code=JCP&vol=24&page=451&goto=abstract
HSL7935
O'Connell CA, Skinner R.
Patient labeling program at Bristol-Myers Squibb
Drug Information Journal 1999; 33:(3):649-654
HSL7967
U.S. pharmaceutical industry spent more than $5.8 billion on product promotion in 1998: direct-to-consumer advertising expenditures exceed $1.3 billion
Massachusetts Pharmacy Journal 1999; 11:(1):12
HSL7975
Danjoh K.
Thinking globally: product development, registration, and marketing in the new millennium
Drug Information Journal 1999; 33:(1):327-332
HSL8137
McKechnie S.
Advertising by pharmaceutical companies in eBMJ.
BMJ 1999; 318:(7183):598
http://www.bmj.com/cgi/content/full/318/7183/598
HSL9053
Irwig J, Irwig L, Sweet M.
Smart Health Choices: How to make informed health decisions
Sydney: Allen & Unwin 1999
http://www.allenandunwin.com/Shopping/ProductDetails.aspx?ISBN=9781865081465
HSL10270
Harada K, Yamazaki S, Arakawa M, Fujimura A.
Survey of the attitudes of pharmacists and medical reprsentative toward drug interactions in daily practice
Japanese Journal of Clinical Pharmacology and Therapeutics 1999; 30:(6):783-791
HSL15128
Chaiken S, Trope Y.
Dual-process theories in social psychology.
New York: Guilford Press 1999
http://books.google.com.au/books?id=5X_auIBx99EC
HSL16245
Fried S
Bitter Pills: Inside the Hazardous World of Legal Drugs New York: Bantam Books 1999
http://www.stephenfried.com/bitter-pills/
HSL19055
Schwartz LM, Woloshin S.
Patient decision making: in search of good decisions.
Eff Clin Pract 1999; 2:(4):184
http://www.acponline.org/clinical_information/journals_publications/ecp/julaug99/woloshin.htm
HSL19056
Woloshin S, Schwartz LM.
How can we help people make sense of medical data?
Eff Clin Pract 1999; 2:(4):176-83
http://www.acponline.org/clinical_information/journals_publications/ecp/julaug99/schwartz.htm
HSL19761
Weston E
A Drug by Any Other Name: Brand Power in the Pharmaceutical Industry
New Doctor 1999; (71):2-7
http://www.drs.org.au/journal/71/71brand.htm
HSL377
Jefferson BK.
Cal Ripken, Jr and Prinivil
;339(27):2024-5. N Engl J Med 1998 Dec 31; 339:(27):2024
http://content.nejm.org/cgi/content/extract/339/27/2024-a?andorexacttitleabs=and&search_tab=authors&tmonth=Dec&searchtitle=Authors&sortspec=Score+desc+PUBDATE_SORTDATE+desc&excludeflag=TWEEK_element&hits=20&tyear=1998&author1=Jefferson+BK&andorexactfulltext=and&fyear=1998&fmonth=Jan&sendit=GO&searchid=1124444608433_740&FIRSTINDEX=0&journalcode=nejm
HSL16734
Wolfe S, Lurie P
Troubling Climate at FDA
The Washington Post 1998 Dec 30
HSL5386
Wood AJ, Stein CM, Woosley R.
Making medicines safer--the need for an independent drug safety board.
N Engl J Med 1998 Dec 17; 339:(25):1851-4
http://content.nejm.org/cgi/content/extract/339/25/1851
HSL8138
Blecher MB, Haugh R, Hudson T, Serb C.
The year that was--what it means for 1999.
Hosp Health Netw 1998 Dec 5-20; 72:(23-24):26-8,
HSL7971
Smith D.
Is your message lost among the rose petals?
Pharmaceutical Executive 1998 Dec; 18:18-19
HSL7972
Realto V.
Best of the best-1998 top 10
Pharmaceutical Executive 1998 Dec; 18:6-11
HSL8177
Mangino MH, Szajna JL, Ptachcinski R, Skledar SJ.
Role of a pharmacy technician in implementing a prescription assistance program for indigent and underinsured patients
ASHP Midyear Clinical Meeting 1998 Dec; 33:
HSL410
Collier J.
Patient-information leaflets and prescriber competence.
Lancet 1998 Nov 28; 352:(9142):1724
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Collier+J&search_within1=au&search_operator1=and&search_text2=leaflets&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL8160
Hui KK.
Adverse drug reactions in hospitalized patients.
JAMA 1998 Nov 25; 280:(20):1742-3
HSL2007
Langreth R.
Drug Marketing Drives Many Clinical Trials
The Wall Street Journal 1998 Nov 16
HSL6835
O’hara J.
Whistle-blower: a top researcher says a drug under trial poses a risk to patients
Maclean’s 1998 Nov 16
HSL8095
Fleming H.
Front-end success
Drug Topics 1998 Nov 16; 142:59-60, 62, 65, 67-68
HSL13868
Hankey GJ.
Heparin in acute ischaemic stroke: The T wave is negative and it's time to stop.
Med J Aust. 1998 Nov 16; 169:(10):534-6
http://www.ncbi.nlm.nih.gov/pubmed/9861911
HSL8169
Consumer ads build awareness but not understanding of advertised medications, surveys reveal
American Journal of Health System Pharmacy 1998 Nov 15; 55:2344, 2347
HSL3697
Scott L.
Patient visits up for DTC conditions.
Newtown, Pa. 1998 Nov 6
http://www.scottlevin.com
HSL4994
McGhan WF.
Employer and consumer perspectives.
Value Health 1998 Nov 01; 1:(4):237-42
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1524-4733.1998.140237.x
HSL394
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov; 44:2376
HSL398
Lal A.
Information contents of drug advertisements: an Indian experience.
Ann Pharmacother 1998 Nov; 32:(11):1234-8
http://www.theannals.com/cgi/reprint/32/11/1234
HSL6832
ACE inhibitors
Health Skepticism 1998 Nov; 1:(1):3-4
HSL6833
Law J.
Assessing the impact of direct-to-consumer advertising
Scrip Magazine 1998 Nov; (73):21-22
HSL6834
Lexchin J.
Re: the promotion of Longifene (buclizine)
1998 Nov;
HSL8110
Wechsler J.
Managed care and pharmaceutical costs
Pharmaceutical Executive 1998 Nov; 18:18, 20-22
HSL8111
Meinhardt RA.
Congress takes aim at retail pharmacy pricing
Drug Benefit Trends 1998 Nov; 10:21-22
HSL8136
Wechsler J.
Costs, coverage, and commercials
Pharmaceutical Technology 1998 Nov; 22:14, 16, 18, 20, 22-24
HSL8165
Pearson P, McWhinney P, Stanley P.
Resistance to antibiotics: Prescribing of antibiotics needs to be rational
British Medical Journal 1998 Nov; 317:1521
http://www.bmj.com/cgi/content/full/317/7171/1521/b
HSL384
Pieters T.
Marketing medicines through randomised controlled trials: the case of interferon.
BMJ 1998 Oct 31; 317:(7167):1231-3
http://bmj.bmjjournals.com/cgi/content/full/317/7167/1231
HSL8163
Sykes R.
Being a modern pharmaceutical company: involves making information available on clinical trial programmes.
BMJ 1998 Oct 31; 317:(7167):1172
http://www.bmj.com/cgi/content/full/317/7167/1172
HSL16733
Wolfe S, Sasich L, Barbehenn E
Safety of sildenafil citrate
Lancet 1998 Oct 24; 352:1393
HSL5313
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.
JAMA 1998 Oct 21; 280:(15):1311-6
http://jama.ama-assn.org/cgi/content/full/280/15/1311
HSL376
Shuchman M.
Legal issues surrounding privately funded research cause furore in Toronto.
CMAJ 1998 Oct 20; 159:(8):983-6
http://www.cmaj.ca/cgi/reprint/159/8/983
HSL385
Phillips RA, Hoey J.
Constraints of interest: lessons at the Hospital for Sick Children.
CMAJ 1998 Oct 20; 159:(8):955-7
http://www.cmaj.ca/cgi/reprint/159/8/955
HSL6831
Drug advertising
Shown on: Canadian Broadcasting Corporation program Undercurrents 1998 Oct 18
HSL370
A meeting too many.
Lancet 1998 Oct 10; 352:(9135):1161
http://linkinghub.elsevier.com/retrieve/pii/S0140673698000324
HSL6823
Bero LA.
Corporate gifts to academic researchers [2nd of 2 replies]
JAMA 1998 Oct 9; 280:(10):884
HSL6824
Campbell EG, Blumental D, Louis KS.
Corporate gifts to academic researchers [1st of 2 replies]
JAMA 1998 Oct 9; 280:(10):884
HSL415
Azimi NA, Welch HG.
The effectiveness of cost-effectiveness analysis in containing costs.
J Gen Intern Med 1998 Oct; 13:(10):664-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00201.x
HSL4782
Phatak A.
The pharmaceutical industry and the medical profession.
Issues Med Ethics 1998 Oct-Dec; 6:(4):131-2
HSL6787
Gabb G.
Striking a balance in drug information--the Australian Medicines Handbook.
Aust N Z J Med 1998 Oct; 28:(5):675
HSL6798
Shapiro JD, Phillips KA, Tannock IF.
More pharmaceutical company influence?
Aust N Z J Med 1998 Oct; 28:(5):675
HSL6822
Aslam N.
Pharmaceuticals lack seriousness to provide more information on request
The Network’s Drug Bulletin 1998 Oct-Dec; 7:(5-6):12-16, 19
HSL6828
The drug pushers
Health Which? 1998 Oct
HSL6829
Lexchin J.
Re: the promotion of Claribid (clarithromycin)
1998 Oct;
HSL6830
Rane W.
How ethical is the pharmaceutical industry in India
Rational Drug Bulletin 1998 Oct; 8:(4):4-5
HSL8116
Morais RJ.
Mastering the basics-10 steps to DTC
Pharmaceutical Executive 1998 Oct; 18:63-65
HSL8117
Wechsler J.
Consumer advocates & pharmacists attack DTC ads
Pharmaceutical Executive 1998 Oct; 18:8, 7
HSL8134
Waltermire RD.
Direct-to-consumer advertising of Rx drugs can be harmful to your health
Drug Benefit Trends 1998 Oct; 10:60-61
HSL8150
Ohliger PC.
Discount or illegal payment?
Drug Benefit Trends 1998 Oct; 10:27, 31
HSL8168
Murray MD, Deardorff FW.
Does managed care fuel pharmaceutical industry growth?
Pharmacoeconomics 1998 Oct; 14:(4):341-8
HSL6827
Public Citizen’s Health Research Group
Comments on: Food and Drug Administration: attitudinal and behavioral effects of direct-to-consumer advertising of prescription drugs
: Public Citizen’s Health Research Group 1998 Sep 28
www.citizen.org
HSL8133
Vecchione A.
All in one
Drug Topics 1998 Sep 21; 142:48
HSL18024
Berger A
The rise and fall of Viagra
BMJ 1998 Sep 19; 317:(7161):824
http://www.bmj.com/cgi/content/citation/317/7161/824
HSL8120
Fleming DJ, Samuels KW.
Direct-to-consumer advertising and the learned intermediary.
Hosp Pract (Minneap) 1998 Sep 15; 33:(9):129-30
HSL6825
Hsu J.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9; 280:(10):883
http://jama.ama-assn.org/cgi/content/full/280/10/883
HSL6826
Trevett KP.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9; 280:(10):883-4
HSL8167
Carbon C, Bax RP.
Regulating the use of antibiotics in the community.
BMJ 1998 Sep 5; 317:(7159):663-5
http://www.bmj.com/cgi/content/full/317/7159/663
HSL401
Kamat VR, Nichter M.
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India.
Soc Sci Med 1998 Sep; 47:(6):779-94
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-3T3SS6V-1H&_coverDate=09%2F16%2F1998&_alid=305663279&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=77260eaace668b4e4f2bdc8361b37ee6
HSL6821
Abbott’s promotion of Claribid (clarithromycin): an example of the use of gifts
MaLAM International News 1998 Sep-Oct; 16:(9-10):1-2
HSL8129
Hewitt A, Jaquiss I.
Particle equation: company viewpoints
Pharmaceutical Executive 1998 Sep; 18:128-130, 132, 134, 136, 138
HSL8130
Petersen C.
I read it over breakfast: print proves its appeal with some all-ink DTC campaigns
Pharmaceutical Executive 1998 Sep; 18:6-8, 10, 12
HSL8131
Madell R.
High energy collision: where medical & consumer marketing intersect
Pharmaceutical Executive 1998 Sep; 18:75-112
HSL8132
Smith D.
Can DTC programs improve patient compliance?
Pharmaceutical Executive 1998 Sep; 18:14, 17
HSL8173
Wechsler J.
Safety first
Pharmaceutical Technology 1998 Sep; 22:16, 18, 20, 22, 24, 26, 28
HSL375
Silversides A.
Private sector becoming the key to research funding in Canada.
CMAJ 1998 Aug 25; 159:(4):397-8
http://www.cmaj.ca/cgi/reprint/159/4/397
HSL396
Lexchin J.
Intellectual property rights and drug prices.
Lancet 1998 Aug 15; 352:(9127):582
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-4FWV34C-NC&_coverDate=08%2F15%2F1998&_alid=305534210&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4886&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=85140d6e65b19947f465cc4160cdcac0
HSL6820
Go on, it’s good for you
The Economist 1998 Aug 851-52
HSL19845
Vawser M
Info on medication samples
Australian Medicine 1998 Aug 37
HSL374
Smith R.
Beyond conflict of interest: Transparency is the key.
BMJ. 1998 Aug 1; 317:(7154):291-2
http://bmj.bmjjournals.com/cgi/content/full/317/7154/291
HSL6818
Consumer and physician attitudes toward direct-to-consumer advertising
: Time Inc. 1998 Aug
HSL8122
Market share plans: NCPA analysis
America's Pharmacist 1998 Aug; 120:25-27
HSL399
Krimsky S, Rothenberg LS.
Financial interest and its disclosure in scientific publications.
JAMA 1998 Jul 15; 280:(3):225-6
http://jama.ama-assn.org/cgi/content/full/280/3/225
HSL18027
Martin RM, Kapoor KV, Wilton LV, Mann RD.
Underreporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study
BMJ 1998 Jul 11; 317:(7151):119-20
http://www.bmj.com/cgi/content/full/317/7151/119?view=long&pmid=9657787
HSL393
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul; 44:1448:
HSL2102
Frances A, Kahn D, Carpenter D, Frances C, Docherty J.
A new method of developing expert consensus practice guidelines.
Am J Manag Care 1998 Jul; 4:(7):1023-9
http://www.ajmc.com/Article.cfm?Menu=1&ID=1662
HSL6815
Mintzes B
Paper tiger or toothless tabby? Regulation of prescription drug promotion in Canada
Vancouver: Health Policy Research Unit 1998 Jul
HSL6816
MaLAM letter follow up—MaLAM apologises but we remain concerned about thepromotion of Atarax
MaLAM International News 1998 Jul-Aug; 16:(7-8):1-5
HSL6817
Sheldon T.
Drug promotion—how ethical is direct-to-consumer advertising?
Scrip Magazine 1998 Jul-Aug; (70):21-22
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6819
Milne C.
Let’s handle drug advertising carefully
Healthcare Manager 1998 Jul-Aug; 3:(5):5
HSL8125
Weiss S.
Generic drug industry: 1998 update
HealthCare Distributors 1998 Jul; 50:38-40, 42, 44
HSL10095
Brewer D.
The effect of drug sampling policies on residents' prescribing.
Fam Med 1998 Jul-Aug; 30:(7):482-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9669159&query_hl=2&itool=pubmed_DocSum
HSL6814
Gilbert D
Direct-to-consumer advertising of prescription medicines
Surrey, United Kingdom: PJB Publications Ltd. 1998 Jun 29
HSL383
Po AL, Zhang WY.
What lessons can be learnt from withdrawal of mibefradil from the market?
Lancet 1998 Jun 20; 351:(9119):1829-30
http://www.thelancet.com/journals/lancet/article/PIIS0140673605788000/fulltext
HSL8178
Denman J.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 3
Journal of the American Medical Association 1998 Jun 17; 279:1876
HSL8179
Sherwood LM.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 2
Journal of the American Medical Association 1998 Jun 17; 279:1876
HSL8180
Hirsch RL.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart Pharmacy: of benefit to whom?
JAMA 1998 Jun 17; 279:(23):1875-6
http://jama.ama-assn.org/cgi/content/full/279/23/1875-a
HSL8191
Hotchkiss BD, Pearson C, Lisitano R.
Pharmacy coordination of an indigent care program in a psychiatric facility.
Am J Health Syst Pharm 1998 Jun 15; 55:(12):1293-6
http://www.ajhp.org/cgi/reprint/55/12/1293
Page 3 of 22 pages < 1 2 3 4 5 > Last ›
